Quincy S. Chu

7.2k total citations · 1 hit paper
134 papers, 4.0k citations indexed

About

Quincy S. Chu is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Quincy S. Chu has authored 134 papers receiving a total of 4.0k indexed citations (citations by other indexed papers that have themselves been cited), including 88 papers in Oncology, 65 papers in Pulmonary and Respiratory Medicine and 34 papers in Molecular Biology. Recurrent topics in Quincy S. Chu's work include Lung Cancer Treatments and Mutations (50 papers), Lung Cancer Research Studies (31 papers) and Cancer Immunotherapy and Biomarkers (22 papers). Quincy S. Chu is often cited by papers focused on Lung Cancer Treatments and Mutations (50 papers), Lung Cancer Research Studies (31 papers) and Cancer Immunotherapy and Biomarkers (22 papers). Quincy S. Chu collaborates with scholars based in Canada, United States and United Kingdom. Quincy S. Chu's co-authors include Vickie E. Baracos, Tony Reiman, Marina Mourtzakis, Rachel A. Murphy, Vera C. Mazurak, Natasha B. Leighl, Eric K. Rowinsky, Barbara Melosky, Lyudmila Bazhenova and Rosalyn A. Juergens and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Quincy S. Chu

129 papers receiving 4.0k citations

Hit Papers

Osimertinib for pretreated EGFR Thr790Met-positive advanc... 2016 2026 2019 2022 2016 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study
    2016 502 citations Frances A. Shepherd, Quincy S. Chu et al. profile →

Peers

Quincy S. Chu
Noriaki Sunaga Japan
Winston Tan United States
Raymond J. Hohl United States
Akira Yokomizo Japan
Jacintha O’Sullivan Ireland
Sui Zhang United States
Coby Meijer Netherlands
Guido Eibl United States
Tohru Utsunomiya Japan
Noriaki Sunaga Japan
Quincy S. Chu
Citations per year, relative to Quincy S. Chu Quincy S. Chu (= 1×) peers Noriaki Sunaga

Countries citing papers authored by Quincy S. Chu

Since Specialization
Citations

This map shows the geographic impact of Quincy S. Chu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Quincy S. Chu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Quincy S. Chu more than expected).

Fields of papers citing papers by Quincy S. Chu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Quincy S. Chu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Quincy S. Chu. The network helps show where Quincy S. Chu may publish in the future.

Co-authorship network of co-authors of Quincy S. Chu

This figure shows the co-authorship network connecting the top 25 collaborators of Quincy S. Chu. A scholar is included among the top collaborators of Quincy S. Chu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Quincy S. Chu. Quincy S. Chu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Melosky, Barbara, Quincy S. Chu, Rosalyn A. Juergens, et al.. (2025). Canadian Perspectives Revisited: Consensus on the management of ALK-rearranged NSCLC. Lung Cancer. 208. 108717–108717.
2.
Meric‐Bernstam, Funda, Martin Gutierrez, Enrique Sanz‐García, et al.. (2025). Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors. Cancer Research Communications. 5(9). 1664–1673. 1 indexed citations
3.
Melosky, Barbara, Rosalyn A. Juergens, Shantanu Banerji, et al.. (2025). The continually evolving landscape of novel therapies in oncogene-driven advanced non-small-cell lung cancer. Therapeutic Advances in Medical Oncology. 17. 12753520–12753520.
4.
Luke, Jason J., Karen A. Gelmon, Lillian L. Siu, et al.. (2024). Phase 1/2 Study of the Indoleamine 2,3-Dioxygenase 1 Inhibitor Linrodostat Mesylate Combined with Nivolumab or Nivolumab and Ipilimumab in Advanced Solid Tumors or Hematologic Malignancies. Clinical Cancer Research. 31(11). 2134–2144. 8 indexed citations
5.
6.
Vaishampayan, Ulka N., Jameel Muzaffar, Ira Winer, et al.. (2024). Nemvaleukin alfa, a modified interleukin-2 cytokine, as monotherapy and with pembrolizumab in patients with advanced solid tumors (ARTISTRY-1). Journal for ImmunoTherapy of Cancer. 12(11). e010143–e010143. 14 indexed citations
7.
Melosky, Barbara, Mark Vincent, Anna McGuire, et al.. (2024). Modern era systemic therapies: Expanding concepts of cure in early and locally advanced non‐small cell lung cancer. International Journal of Cancer. 155(6). 963–978. 3 indexed citations
8.
Snow, Stephanie, Paul Wheatley‐Price, Barbara Melosky, et al.. (2023). Lorlatinib Effectiveness and Quality-of-Life in Patients with ALK-Positive NSCLC Who Had Failed Second-Generation ALK Inhibitors: Canadian Real-World Experience. Current Oncology. 30(7). 6559–6574. 4 indexed citations
9.
Cheema, Parneet, Shantanu Banerji, Normand Blais, et al.. (2023). Canadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLC. Current Oncology. 30(7). 6473–6496. 1 indexed citations
10.
Tankel, James, Jonathan Spicer, Quincy S. Chu, et al.. (2023). Canadian Consensus Recommendations for the Management of Operable Stage II/III Non-Small-Cell Lung Cancer: Results of a Modified Delphi Process. Current Oncology. 30(12). 10363–10384. 4 indexed citations
11.
Bauer, Todd M., Kathleen N. Moore, Janet S. Rader, et al.. (2023). A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors. Targeted Oncology. 18(4). 517–530. 21 indexed citations
12.
Rottey, Sylvie, Jeffrey Clarke, Kyaw Aung, et al.. (2022). Phase I/IIa Trial of BMS-986148, an Anti-mesothelin Antibody-drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors. EUR Research Repository (Erasmus University Rotterdam). 40 indexed citations
13.
Ionescu, Diana N., Tracy Stockley, Shantanu Banerji, et al.. (2022). Consensus Recommendations to Optimize Testing for New Targetable Alterations in Non-Small Cell Lung Cancer. Current Oncology. 29(7). 4981–4997. 20 indexed citations
14.
15.
Melosky, Barbara, Parneet Cheema, Rosalyn A. Juergens, et al.. (2021). The dawn of a new era, adjuvant EGFR inhibition in resected non-small cell lung cancer. Therapeutic Advances in Medical Oncology. 13. 4277468338–4277468338. 4 indexed citations
16.
Melosky, Barbara, Paul Wheatley‐Price, Rosalyn A. Juergens, et al.. (2021). The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer. Lung Cancer. 160. 136–151. 51 indexed citations
17.
Melosky, Barbara, Rosalyn A. Juergens, Deanna McLeod, et al.. (2019). Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer. Lung Cancer. 134. 259–267. 30 indexed citations
18.
Brade, Anthony, Robert M. MacRae, Scott A. Laurie, et al.. (2015). Phase II Study of Concurrent Pemetrexed, Cisplatin, and Radiation Therapy for Stage IIIA/B Unresectable Non–Small Cell Lung Cancer. Clinical Lung Cancer. 17(2). 133–141. 8 indexed citations
19.
Goel, Sanjay, Alain C. Mita, Monica Mita, et al.. (2009). A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies. Clinical Cancer Research. 15(12). 4207–4212. 121 indexed citations
20.
Mita, Monica, Alain C. Mita, Quincy S. Chu, et al.. (2008). Phase I Trial of the Novel Mammalian Target of Rapamycin Inhibitor Deforolimus (AP23573; MK-8669) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients With Advanced Malignancies. Journal of Clinical Oncology. 26(3). 361–367. 227 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Noriaki Sunaga Breakdown of academic impact, for papers by Winston Tan Breakdown of academic impact, for papers by Raymond J. Hohl Breakdown of academic impact, for papers by Akira Yokomizo Breakdown of academic impact, for papers by Jacintha O’Sullivan Breakdown of academic impact, for papers by Sui Zhang Breakdown of academic impact, for papers by Coby Meijer Breakdown of academic impact, for papers by Guido Eibl Breakdown of academic impact, for papers by Tohru Utsunomiya
Rankless by CCL
2026